Osimertinib is a third-generation epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki) drug for mutated egfr cancers.osimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (nsclc), when the cancer has the specific t790m mutation in the gene coding for epidermal growth factor receptor.